Literature DB >> 2676656

Interaction of beta-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans.

J P Palmer, S Helqvist, G A Spinas, J Mølvig, T Mandrup-Poulsen, H U Andersen, J Nerup.   

Abstract

This study was designed to test the hypothesis that target-cell activity influences the degree and time course of interleukin 1 beta (IL-1 beta)-mediated beta-cell impairment in vitro. Functional and morphological studies were performed in cultured newborn rat islets of Langerhans exposed from 6 h to 6 days to 50-2000 ng/L recombinant human IL-1 beta. Beta-Cell activity was modulated by glucose and nonglucose agents (15 mM L-leucine and 10 microM of long-acting somatostatin analogue SMS 201-995). In 11 mM glucose, 2000 ng/L of IL-1 beta caused inhibition of insulin release after approximately 6 h of exposure to IL-1 beta; in 3.3 mM glucose culture, onset of inhibition was delayed by this IL-1 beta concentration until after 48 h of exposure. Similarly, stimulation and suppression of beta-cell function with L-leucine and SMS 201-995, respectively, resulted in acceleration and delay of IL-1 beta-mediated inhibition. The dose-response curve of the IL-1 beta effect was shifted left- and rightward during high and low beta-cell activity, respectively. In analogy, increasing IL-1 beta concentration, exposure time, and beta-cell activity resulted in increasing islet disintegration. Thus, the resting beta-cell is more resistant to IL-1 beta-mediated impairment than the working beta-cell.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676656     DOI: 10.2337/diab.38.10.1211

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  41 in total

1.  The battered β-cell: usual suspects and guilt by association.

Authors:  R Paul Robertson
Journal:  J Clin Endocrinol Metab       Date:  2011-12       Impact factor: 5.958

Review 2.  Environmental triggers of type 1 diabetes.

Authors:  Mikael Knip; Olli Simell
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  FoxO1 and SIRT1 regulate beta-cell responses to nitric oxide.

Authors:  Katherine J Hughes; Gordon P Meares; Polly A Hansen; John A Corbett
Journal:  J Biol Chem       Date:  2011-01-01       Impact factor: 5.157

Review 4.  Blockade of interleukin 1 in type 1 diabetes mellitus.

Authors:  Thomas Mandrup-Poulsen; Linda Pickersgill; Marc Yves Donath
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

5.  Microencapsulated islet grafts in the BB/E rat: a possible role for cytokines in graft failure.

Authors:  D R Cole; M Waterfall; M McIntyre; J D Baird
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

Review 6.  Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes.

Authors:  Thomas Mandrup-Poulsen
Journal:  Rev Diabet Stud       Date:  2012-12-28

7.  Glucose activation of islets of Langerhans up-regulates Toll-like receptor 5: possible mechanism of protection.

Authors:  C Weile; K Josefsen; K Buschard
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

8.  Extracellular factors and immunosuppressive drugs influencing insulin secretion of murine islets.

Authors:  V J Auer; E Janas; V Ninichuk; E Eppler; T S Weiss; S Kirchner; A M Otto; M J Stangl
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

9.  Interleukin-1 signaling contributes to acute islet compensation.

Authors:  Catherine Hajmrle; Nancy Smith; Aliya F Spigelman; Xiaoqing Dai; Laura Senior; Austin Bautista; Mourad Ferdaoussi; Patrick E MacDonald
Journal:  JCI Insight       Date:  2016-04-07

10.  Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis?

Authors:  Laerke Egefjord; Jens Ledet Jensen; Claus Heiner Bang-Berthelsen; Andreas Brønden Petersen; Kamille Smidt; Ole Schmitz; Allan Ertman Karlsen; Flemming Pociot; Fabrice Chimienti; Jørgen Rungby; Nils E Magnusson
Journal:  BMC Endocr Disord       Date:  2009-02-25       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.